Home > Insider Trading > Filing (0001567619-22-021865)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1623715	Imago Biosciences Inc.	IMGO	Pharmaceutical Preparations (2834)	454915810

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1861069	E. Amy Tapper	C/O Imago Biosciences, Inc. 303 Twin Dolphin Drive, 6Th Floor Redwood City CA 94065	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-12-16	29,461	$2.10	148,508	No	4	M	Direct
Common Stock	Acquisiton	2022-12-16	5,952	$2.19	154,460	No	4	M	Direct
Common Stock	Acquisiton	2022-12-16	2,380	$2.27	156,840	No	4	M	Direct
Common Stock	Acquisiton	2022-12-16	44,500	$2.52	201,340	No	4	M	Direct
Common Stock	Acquisiton	2022-12-16	18,009	$1.52	219,349	No	4	M	Direct
Common Stock	Disposition	2022-12-16	100,302	$35.78	119,047	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to buy)	Disposition	2022-12-16	29,461	$0.00	29,461	$2.10
Common Stock	Stock Option (Right to buy)	Disposition	2022-12-16	5,952	$0.00	5,952	$2.19
Common Stock	Stock Option (Right to buy)	Disposition	2022-12-16	2,380	$0.00	2,380	$2.27
Common Stock	Stock Option (Right to buy)	Disposition	2022-12-16	44,500	$0.00	44,500	$2.52
Common Stock	Stock Option (Right to buy)	Disposition	2022-12-16	18,009	$0.00	18,009	$1.52

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
23,562		2030-09-09	No	4	M	Direct
0	2019-11-17	2025-11-16	No	4	M	Direct
0	2020-11-09	2026-11-08	No	4	M	Direct
8,232	2021-01-01	2027-03-28	No	4	M	Direct
2,729		2029-04-09	No	4	M	Direct

Footnotes

The transaction was executed in multiple trades in prices ranging from $35.77 to $35.79, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The Option vests with respect to 25% of the shares subject thereto on July 7, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from April 10, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.